NeoGenomics, Inc. (NEO)
Nasdaq · Healthcare · Diagnostics & Research
$19.13+3.57%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.5B
- Forward P/E
- 56.6
- 52-week range
- $7.07 – $20.05
- 52-week change
- +102.97%
- EPS (trailing)
- −$0.39
- Analyst rating
- 1.8 Buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $727M (+10.11%)
- Net income
- −$108M
- Operating margin
- −15.9%
- Free cash flow
- −$21.8M
From the company’s annual report on SEC EDGAR.
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
Headquarters: Fort Myers, United States · 2,500 employees · neogenomics.com